Probing the Biology of Alzheimer's Disease in Mice

Neuron

Volumn 66, Issue 5, 2010, Pages 631-645

  Ashe, Karen H ^a,b   Zahs, Kathleen R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; BRAIN ATROPHY; COGNITIVE DEFECT; DISEASE COURSE; DISEASE MODEL; GENE MUTATION; HUMAN; LINKAGE ANALYSIS; MEMORY DISORDER; NERVE CELL EXCITABILITY; NERVE CELL NECROSIS; NERVE INJURY; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; SYNAPTIC TRANSMISSION; TRANSGENIC MOUSE; VASCULAR AMYLOIDOSIS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; TAU PROTEINS;

EID: 77953675879     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuron.2010.04.031     Document Type: Review

References (204)

1. Adams M.M., Smith T.D., Moga D., Gallagher M., Wang Y., Wolfe B.B., Rapp P.R., Morrison J.H. Hippocampal dependent learning ability correlates with N-methyl-D-aspartate (NMDA) receptor levels in CA3 neurons of young and aged rats. J. Comp. Neurol. 2001, 432:230-243.
2. Amador-Ortiz C., Lin W.L., Ahmed Z., Personett D., Davies P., Duara R., Graff-Radford N.R., Hutton M.L., Dickson D.W. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann. Neurol. 2007, 61:435-445.
3. Andorfer C., Kress Y., Espinoza M., de Silva R., Tucker K.L., Barde Y.A., Duff K., Davies P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 2003, 86:582-590.
4. Andorfer C., Acker C.M., Kress Y., Hof P.R., Duff K., Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J. Neurosci. 2005, 25:5446-5454.
5. Banks W.A., Farr S.A., Butt W., Kumar V.B., Franko M.W., Morley J.E. Delivery across the blood-brain barrier of antisense directed against amyloid beta: reversal of learning and memory deficits in mice overexpressing amyloid precursor protein. J. Pharmacol. Exp. Ther. 2001, 297:1113-1121.
6. Barnes C.A. Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat. J. Comp. Physiol. Psychol. 1979, 93:74-104.
7. Bennett D.A., Schneider J.A., Wilson R.S., Bienias J.L., Arnold S.E. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch. Neurol. 2004, 61:378-384.
8. Bennett D.A., Schneider J.A., Arvanitakis Z., Kelly J.F., Aggarwal N.T., Shah R.C., Wilson R.S. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006, 66:1837-1844.
9. Berger Z., Roder H., Hanna A., Carlson A., Rangachari V., Yue M., Wszolek Z., Ashe K., Knight J., Dickson D., et al. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J. Neurosci. 2007, 27:3650-3662.
10. Billings L.M., Oddo S., Green K.N., McGaugh J.L., LaFerla F.M. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005, 45:675-688.
11. Bishnoi M., Patil C.S., Kumar A., Kulkarni S.K. Protective effects of nimesulide (COX Inhibitor), AKBA (5-LOX Inhibitor), and their combination in aging-associated abnormalities in mice. Methods Find. Exp. Clin. Pharmacol. 2005, 27:465-470.
12. Bizon J.L., Helm K.A., Han J.S., Chun H.J., Pucilowska J., Lund P.K., Gallagher M. Hypothalamic-pituitary-adrenal axis function and corticosterone receptor expression in behaviourally characterized young and aged Long-Evans rats. Eur. J. Neurosci. 2001, 14:1739-1751.
13. Boekhoorn K., Terwel D., Biemans B., Borghgraef P., Wiegert O., Ramakers G.J., de Vos K., Krugers H., Tomiyama T., Mori H., et al. Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy. J. Neurosci. 2006, 26:3514-3523.
14. Bolmont T., Clavaguera F., Meyer-Luehmann M., Herzig M.C., Radde R., Staufenbiel M., Lewis J., Hutton M., Tolnay M., Jucker M. Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am. J. Pathol. 2007, 171:2012-2020.
15. Boric K., Muñoz P., Gallagher M., Kirkwood A. Potential adaptive function for altered long-term potentiation mechanisms in aging hippocampus. J. Neurosci. 2008, 28:8034-8039.
16. Bronfman F.C., Moechars D., Van Leuven F. Acetylcholinesterase-positive fiber deafferentation and cell shrinkage in the septohippocampal pathway of aged amyloid precursor protein london mutant transgenic mice. Neurobiol. Dis. 2000, 7:152-168.
17. Brouwers N., Sleegers K., Van Broeckhoven C. Molecular genetics of Alzheimer's disease: an update. Ann. Med. 2008, 40:562-583.
18. Busche M.A., Eichhoff G., Adelsberger H., Abramowski D., Wiederhold K.H., Haass C., Staufenbiel M., Konnerth A., Garaschuk O. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science 2008, 321:1686-1689.
19. Buxbaum J.D., Thinakaran G., Koliatsos V., O'Callahan J., Slunt H.H., Price D.L., Sisodia S.S. Alzheimer amyloid protein precursor in the rat hippocampus: transport and processing through the perforant path. J. Neurosci. 1998, 18:9629-9637.
20. Capsoni S., Cattaneo A. On the molecular basis linking Nerve Growth Factor (NGF) to Alzheimer's disease. Cell. Mol. Neurobiol. 2006, 26:619-633.
21. Caselli R.J., Chen K., Lee W., Alexander G.E., Reiman E.M. Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment. Arch. Neurol. 2008, 65:1231-1236.
22. Cha J.H., Farrell L.A., Ahmed S.F., Frey A., Hsiao-Ashe K.K., Young A.B., Penney J.B., Locascio J.J., Hyman B.T., Irizarry M.C. Glutamate receptor dysregulation in the hippocampus of transgenic mice carrying mutated human amyloid precursor protein. Neurobiol. Dis. 2001, 8:90-102.
23. Chapman P.F., White G.L., Jones M.W., Cooper-Blacketer D., Marshall V.J., Irizarry M., Younkin L., Good M.A., Bliss T.V., Hyman B.T., et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 1999, 2:271-276.
24. Chartier-Harlin M.-C., Crawford F., Houlden H., Warren A., Hughes D., Fidani L., Goate A., Rossor M., Roques P., Hardy J., Mullan M. Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene. Nature 1991, 353:844-846.
25. Cheng I.H., Palop J.J., Esposito L.A., Bien-Ly N., Yan F., Mucke L. Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat. Med. 2004, 10:1190-1192.
26. Cheng I.H., Scearce-Levie K., Legleiter J., Palop J.J., Gerstein H., Bien-Ly N., Puoliväli J., Lesné S., Ashe K.H., Muchowski P.J., Mucke L. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 2007, 282:23818-23828.
27. Chin J., Palop J.J., Puoliväli J., Massaro C., Bien-Ly N., Gerstein H., Scearce-Levie K., Masliah E., Mucke L. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 2005, 25:9694-9703.
28. Chin, J., Ling, H.-P., Comery, T., Pangalos, M., Reinhart, P., and Wood, A. (2007). Chronic imbalance in neuronal activity and compensatory plasticity are associated with cognitive impairment in Tg2576 and PS1/APP mouse models of Alzheimer's disease. In International Conference on Alzheimer's Disease (Chicago, IL).
29. Chishti M.A., Yang D.S., Janus C., Phinney A.L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 2001, 276:21562-21570.
30. Cirrito J.R., Yamada K.A., Finn M.B., Sloviter R.S., Bales K.R., May P.C., Schoepp D.D., Paul S.M., Mennerick S., Holtzman D.M. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 2005, 48:913-922.
31. Colombo P.J., Gallagher M. Individual differences in spatial memory among aged rats are related to hippocampal PKCgamma immunoreactivity. Hippocampus 2002, 12:285-289.
32. Colombo P.J., Wetsel W.C., Gallagher M. Spatial memory is related to hippocampal subcellular concentrations of calcium-dependent protein kinase C isoforms in young and aged rats. Proc. Natl. Acad. Sci. USA 1997, 94:14195-14199.
33. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
34. Costa D.A., Cracchiolo J.R., Bachstetter A.D., Hughes T.F., Bales K.R., Paul S.M., Mervis R.F., Arendash G.W., Potter H. Enrichment improves cognition in AD mice by amyloid-related and unrelated mechanisms. Neurobiol. Aging 2007, 28:831-844.
35. Cruts M., Van Broeckhoven C. Molecular genetics of Alzheimer's disease. Ann. Med. 1998, 30:560-565.
36. Dawson G.R., Seabrook G.R., Zheng H., Smith D.W., Graham S., O'Dowd G., Bowery B.J., Boyce S., Trumbauer M.E., Chen H.Y., et al. Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience 1999, 90:1-13.
37. Dawson H.N., Ferreira A., Eyster M.V., Ghoshal N., Binder L.I., Vitek M.P. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J. Cell Sci. 2001, 114:1179-1187.
38. de Leon M.J., Ferris S.H., George A.E., Christman D.R., Fowler J.S., Gentes C., Reisberg B., Gee B., Emmerich M., Yonekura Y., et al. Positron emission tomographic studies of aging and Alzheimer disease. AJNR Am. J. Neuroradiol. 1983, 4:568-571.
39. de Leon M.J., Convit A., Wolf O.T., Tarshish C.Y., DeSanti S., Rusinek H., Tsui W., Kandil E., Scherer A.J., Roche A., et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc. Natl. Acad. Sci. USA 2001, 98:10966-10971.
40. de Leon M.J., Mosconi L., Blennow K., DeSanti S., Zinkowski R., Mehta P.D., Pratico D., Tsui W., Saint Louis L.A., Sobanska L., et al. Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann. N Y Acad. Sci. 2007, 1097:114-145.
41. de Toledo-Morrell L., Goncharova I., Dickerson B., Wilson R.S., Bennett D.A. From healthy aging to early Alzheimer's disease: in vivo detection of entorhinal cortex atrophy. Ann. N Y Acad. Sci. 2000, 911:240-253.
42. Del Vecchio R.A., Gold L.H., Novick S.J., Wong G., Hyde L.A. Increased seizure threshold and severity in young transgenic CRND8 mice. Neurosci. Lett. 2004, 367:164-167.
43. den Heijer T., Geerlings M.I., Hoebeek F.E., Hofman A., Koudstaal P.J., Breteler M.M. Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. Arch. Gen. Psychiatry 2006, 63:57-62.
44. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., Paul S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 2002, 5:452-457.
45. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6:734-746.
46. Dumont M., Wille E., Stack C., Calingasan N.Y., Beal M.F., Lin M.T. Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J. 2009, 23:2459-2466.
47. Duyckaerts C., Potier M.C., Delatour B. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol. 2008, 115:5-38.
48. Finch C.E. Neuron atrophy during aging: programmed or sporadic?. Trends Neurosci. 1993, 16:104-110.
49. Foster T.C. Calcium homeostasis and modulation of synaptic plasticity in the aged brain. Aging Cell 2007, 6:319-325.
50. Foster N.L. A new framework for the diagnosis of Alzheimer's disease. Lancet Neurol. 2007, 6:667-669.
51. Fukumoto H., Rosene D.L., Moss M.B., Raju S., Hyman B.T., Irizarry M.C. Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am. J. Pathol. 2004, 164:719-725.
52. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995, 373:523-527.
53. Giannakopoulos P., Herrmann F.R., Bussière T., Bouras C., Kövari E., Perl D.P., Morrison J.H., Gold G., Hof P.R. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003, 60:1495-1500.
54. Glenner G.G., Wong C.W. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 1984, 122:1131-1135.
55. Goate A.M., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991, 349:704-706.
56. Goldgaber D., Lerman M.I., McBride O.W., Saffiotti U., Gajdusek D.C. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 1987, 235:877-880.
57. Gómez-Isla T., Hollister R., West H., Mui S., Growdon J.H., Petersen R.C., Parisi J.E., Hyman B.T. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 1997, 41:17-24.
58. Gordon M.N., King D.L., Diamond D.M., Jantzen P.T., Boyett K.V., Hope C.E., Hatcher J.M., DiCarlo G., Gottschall W.P., Morgan D., Arendash G.W. Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiol. Aging 2001, 22:377-385.
59. Götz J., Chen F., Barmettler R., Nitsch R.M. Tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem. 2001, 276:529-534.
60. Götz J., Chen F., van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001, 293:1491-1495.
61. Green K.N., LaFerla F.M. Linking calcium to Abeta and Alzheimer's disease. Neuron 2008, 59:190-194.
62. Grober E., Dickson D., Sliwinski M.J., Buschke H., Katz M., Crystal H., Lipton R.B. Memory and mental status correlates of modified Braak staging. Neurobiol. Aging 1999, 20:573-579.
63. Gureviciene I., Ikonen S., Gurevicius K., Sarkaki A., van Groen T., Pussinen R., Ylinen A., Tanila H. Normal induction but accelerated decay of LTP in APP + PS1 transgenic mice. Neurobiol. Dis. 2004, 15:188-195.
64. Hajieva P., Kuhlmann C., Luhmann H.J., Behl C. Impaired calcium homeostasis in aged hippocampal neurons. Neurosci. Lett. 2009, 451:119-123.
65. Harada A., Oguchi K., Okabe S., Kuno J., Terada S., Ohshima T., Sato-Yoshitake R., Takei Y., Noda T., Hirokawa N. Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 1994, 369:488-491.
66. Harburger L.L., Lambert T.J., Frick K.M. Age-dependent effects of environmental enrichment on spatial reference memory in male mice. Behav. Brain Res. 2007, 185:43-48.
67. Harburger L.L., Nzerem C.K., Frick K.M. Single enrichment variables differentially reduce age-related memory decline in female mice. Behav. Neurosci. 2007, 121:679-688.
68. Hardy J. A hundred years of Alzheimer's disease research. Neuron 2006, 52:3-13.
69. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
70. Higashi S., Iseki E., Yamamoto R., Minegishi M., Hino H., Fujisawa K., Togo T., Katsuse O., Uchikado H., Furukawa Y., et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Res. 2007, 1184:284-294.
71. Holcomb L.A., Gordon M.N., Jantzen P., Hsiao K., Duff K., Morgan D. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav. Genet. 1999, 29:177-185.
72. Hsiao K.K., Borchelt D.R., Olson K., Johannsdottir R., Kitt C., Yunis W., Xu S., Eckman C., Younkin S., Price D., et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 1995, 15:1203-1218.
73. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
74. Hu D., Cao P., Thiels E., Chu C.T., Wu G.Y., Oury T.D., Klann E. Hippocampal long-term potentiation, memory, and longevity in mice that overexpress mitochondrial superoxide dismutase. Neurobiol. Learn. Mem. 2007, 87:372-384.
75. Hulette C.M., Welsh-Bohmer K.A., Murray M.G., Saunders A.M., Mash D.C., McIntyre L.M. Neuropathological and neuropsychological changes in " normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J. Neuropathol. Exp. Neurol. 1998, 57:1168-1174.
76. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat. Rev. Neurosci. 2004, 5:347-360.
77. Ikegami S., Harada A., Hirokawa N. Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice. Neurosci. Lett. 2000, 279:129-132.
78. Irizarry M.C., McNamara M., Fedorchak K., Hsiao K., Hyman B.T. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 1997, 56:965-973.
79. Irizarry M.C., Soriano F., McNamara M., Page K.J., Schenk D., Games D., Hyman B.T. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 1997, 17:7053-7059.
80. Ishihara T., Zhang B., Higuchi M., Yoshiyama Y., Trojanowski J.Q., Lee V.M. Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice. Am. J. Pathol. 2001, 158:555-562.
81. Jain N.K., Patil C.S., Kulkarni S.K., Singh A. Modulatory role of cyclooxygenase inhibitors in aging- and scopolamine or lipopolysaccharide-induced cognitive dysfunction in mice. Behav. Brain Res. 2002, 133:369-376.
82. Jankowsky J.L., Melnikova T., Fadale D.J., Xu G.M., Slunt H.H., Gonzales V., Younkin L.H., Younkin S.G., Borchelt D.R., Savonenko A.V. Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J. Neurosci. 2005, 25:5217-5224.
83. Jolas T., Zhang X.S., Zhang Q., Wong G., Del Vecchio R., Gold L., Priestley T. Long-term potentiation is increased in the CA1 area of the hippocampus of APP(swe/ind) CRND8 mice. Neurobiol. Dis. 2002, 11:394-409.
84. Josephs K.A., Whitwell J.L., Knopman D.S., Hu W.T., Stroh D.A., Baker M., Rademakers R., Boeve B.F., Parisi J.E., Smith G.E., et al. Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology 2008, 70:1850-1857.
85. Kadokura A., Yamazaki T., Lemere C.A., Takatama M., Okamoto K. Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology. Neuropathology 2009, 29:566-573.
86. Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., Sisodia S., Malinow R. APP processing and synaptic function. Neuron 2003, 37:925-937.
87. Kang J., Lemaire H.-G., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K.-H., Multhaup G., Beyreuther K., Müller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325:733-736.
88. Kim J., Basak J.M., Holtzman D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303.
89. Knight W.D., Kim L.G., Douiri A., Frost C., Rossor M.N., Fox N.C. Acceleration of cortical thinning in familial Alzheimer's disease. Neurobiol. Aging 2009, in press. Published online December 14, 2009. 10.1016/j.neurobiolaging.2009.11.013.
90. Knowles R.B., Wyart C., Buldyrev S.V., Cruz L., Urbanc B., Hasselmo M.E., Stanley H.E., Hyman B.T. Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 1999, 96:5274-5279.
91. Koffie R.M., Meyer-Luehmann M., Hashimoto T., Adams K.W., Mielke M.L., Garcia-Alloza M., Micheva K.D., Smith S.J., Kim M.L., Lee V.M., et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. USA 2009, 106:4012-4017.
92. Koo E.H., Sisodia S.S., Archer D.R., Martin L.J., Weidemann A., Beyreuther K., Fischer P., Masters C.L., Price D.L. Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc. Natl. Acad. Sci. USA 1990, 87:1561-1565.
93. Korczyn A.D. Mixed dementia-the most common cause of dementia. Ann. N Y Acad. Sci. 2002, 977:129-134.
94. Kotilinek L.A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B.T., Younkin S., Ashe K.H. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 2002, 22:6331-6335.
95. Kotilinek L.A., Westerman M.A., Wang Q., Panizzon K., Lim G.P., Simonyi A., Lesné S., Falinska A., Younkin L.H., Younkin S.G., et al. Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain 2008, 131:651-664.
96. Kovacs G.G., Alafuzoff I., Al-Sarraj S., Arzberger T., Bogdanovic N., Capellari S., Ferrer I., Gelpi E., Kövari V., Kretzschmar H., et al. Mixed brain pathologies in dementia: the BrainNet Europe consortium experience. Dement. Geriatr. Cogn. Disord. 2008, 26:343-350.
97. Kumar A., Schapiro M.B., Grady C., Haxby J.V., Wagner E., Salerno J.A., Friedland R.P., Rapoport S.I. High-resolution PET studies in Alzheimer's disease. Neuropsychopharmacology 1991, 4:35-46.
98. Kumar V.B., Farr S.A., Flood J.F., Kamlesh V., Franko M., Banks W.A., Morley J.E. Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice. Peptides 2000, 21:1769-1775.
99. Laird F.M., Cai H., Savonenko A.V., Farah M.H., He K., Melnikova T., Wen H., Chiang H.C., Xu G., Koliatsos V.E., et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci. 2005, 25:11693-11709.
100. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 1998, 95:6448-6453.
101. Langa K.M., Foster N.L., Larson E.B. Mixed dementia: emerging concepts and therapeutic implications. JAMA 2004, 292:2901-2908.
102. Lehman E.J., Kulnane L.S., Lamb B.T. Alterations in beta-amyloid production and deposition in brain regions of two transgenic models. Neurobiol. Aging 2003, 24:645-653.
103. Lesné S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
104. Lesné S., Kotilinek L., Ashe K.H. Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function. Neuroscience 2008, 151:745-749.
105. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001, 293:1487-1491.
106. Lleó A., Berezovska O., Growdon J.H., Hyman B.T. Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am. J. Geriatr. Psychiatry 2004, 12:146-156.
107. Loerch P.M., Lu T., Dakin K.A., Vann J.M., Isaacs A., Geula C., Wang J., Pan Y., Gabuzda D.H., Li C., et al. Evolution of the aging brain transcriptome and synaptic regulation. PLoS ONE 2008, 3:e3329.
108. Ma H., Lesné S., Kotilinek L., Steidl-Nichols J.V., Sherman M., Younkin L., Younkin S., Forster C., Sergeant N., Delacourte A., et al. Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. Proc. Natl. Acad. Sci. USA 2007, 104:8167-8172.
109. Ma Q.L., Yang F., Calon F., Ubeda O.J., Hansen J.E., Weisbart R.H., Beech W., Frautschy S.A., Cole G.M. p21-activated kinase-aberrant activation and translocation in Alzheimer disease pathogenesis. J. Biol. Chem. 2008, 283:14132-14143.
110. Mandelkow E.M., Stamer K., Vogel R., Thies E., Mandelkow E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol. Aging 2003, 24:1079-1085.
111. Martin S.J., Grimwood P.D., Morris R.G. Synaptic plasticity and memory: an evaluation of the hypothesis. Annu. Rev. Neurosci. 2000, 23:649-711.
112. Meyer-Luehmann M., Spires-Jones T.L., Prada C., Garcia-Alloza M., de Calignon A., Rozkalne A., Koenigsknecht-Talboo J., Holtzman D.M., Bacskai B.J., Hyman B.T. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 2008, 451:720-724.
113. Meziane H., Dodart J.C., Mathis C., Little S., Clemens J., Paul S.M., Ungerer A. Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice. Proc. Natl. Acad. Sci. USA 1998, 95:12683-12688.
114. Minkeviciene R., Rheims S., Dobszay M.B., Zilberter M., Hartikainen J., Fülöp L., Penke B., Zilberter Y., Harkany T., Pitkänen A., Tanila H. Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J. Neurosci. 2009, 29:3453-3462.
115. Mondadori C.R., Buchmann A., Mustovic H., Schmidt C.F., Boesiger P., Nitsch R.M., Hock C., Streffer J., Henke K. Enhanced brain activity may precede the diagnosis of Alzheimer's disease by 30 years. Brain 2006, 129:2908-2922.
116. Morley J.E., Kumar V.B., Bernardo A.E., Farr S.A., Uezu K., Tumosa N., Flood J.F. Beta-amyloid precursor polypeptide in SAMP8 mice affects learning and memory. Peptides 2000, 21:1761-1767.
117. Morris J.C., Roe C.M., Grant E.A., Head D., Storandt M., Goate A.M., Fagan A.M., Holtzman D.M., Mintun M.A. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol. 2009, 66:1469-1475.
118. Mosconi L., Sorbi S., de Leon M.J., Li Y., Nacmias B., Myoung P.S., Tsui W., Ginestroni A., Bessi V., Fayyazz M., et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J. Nucl. Med. 2006, 47:1778-1786.
119. Mosconi L., De Santi S., Li J., Tsui W.H., Li Y., Boppana M., Laska E., Rusinek H., de Leon M.J. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol. Aging 2008, 29:676-692.
120. Mouton P.R., Chachich M.E., Quigley C., Spangler E., Ingram D.K. Caloric restriction attenuates amyloid deposition in middle-aged dtg APP/PS1 mice. Neurosci. Lett. 2009, 464:184-187.
121. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000, 20:4050-4058.
122. Mullan M., Crawford F., Axelman K., Houlden H., Lilius L., Winblad B., Lannfelt L. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat. Genet. 1992, 1:345-347.
123. Murrell J., Farlow M., Ghetti B., Benson M.D. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 1991, 254:97-99.
124. Murrell J.R., Hake A.M., Quaid K.A., Farlow M.R., Ghetti B. Early-onset Alzheimer disease caused by a new mutation (V717L) in the amyloid precursor protein gene. Arch. Neurol. 2000, 57:885-887.
125. Nicolle M.M., Bizon J.L., Gallagher M. In vitro autoradiography of ionotropic glutamate receptors in hippocampus and striatum of aged Long-Evans rats: relationship to spatial learning. Neuroscience 1996, 74:741-756.
126. Nicolle M.M., Gonzalez J., Sugaya K., Baskerville K.A., Bryan D., Lund K., Gallagher M., McKinney M. Signatures of hippocampal oxidative stress in aged spatial learning-impaired rodents. Neuroscience 2001, 107:415-431.
127. Nikolaev A., McLaughlin T., O'Leary D.D., Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009, 457:981-989.
128. Nilsberth C., Westlind-Danielsson A., Eckman C.B., Condron M.M., Axelman K., Forsell C., Stenh C., Luthman J., Teplow D.B., Younkin S.G., et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat. Neurosci. 2001, 4:887-893.
129. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
130. Oddo S., Billings L., Kesslak J.P., Cribbs D.H., LaFerla F.M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004, 43:321-332.
131. Oddo S., Vasilevko V., Caccamo A., Kitazawa M., Cribbs D.H., LaFerla F.M. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem. 2006, 281:39413-39423.
132. Okuma Y., Nomura Y. Senescence-accelerated mouse (SAM) as an animal model of senile dementia: pharmacological, neurochemical and molecular biological approach. Jpn. J. Pharmacol. 1998, 78:399-404.
133. Palop J.J., Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch. Neurol. 2009, 66:435-440.
134. Palop J.J., Chin J., Roberson E.D., Wang J., Thwin M.T., Bien-Ly N., Yoo J., Ho K.O., Yu G.Q., Kreitzer A., et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007, 55:697-711.
135. Pappolla M.A., Chyan Y.J., Poeggeler B., Bozner P., Ghiso J., LeDoux S.P., Wilson G.L. Alzheimer beta protein mediated oxidative damage of mitochondrial DNA: prevention by melatonin. J. Pineal Res. 1999, 27:226-229.
136. Patel N.V., Gordon M.N., Connor K.E., Good R.A., Engelman R.W., Mason J., Morgan D.G., Morgan T.E., Finch C.E. Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiol. Aging 2005, 26:995-1000.
137. Pedersen W.A., Culmsee C., Ziegler D., Herman J.P., Mattson M.P. Aberrant stress response associated with severe hypoglycemia in a transgenic mouse model of Alzheimer's disease. J. Mol. Neurosci. 1999, 13:159-165.
138. Petersen R.C., Negash S. Mild cognitive impairment: an overview. CNS Spectr. 2008, 13:45-53.
139. Petrie E.C., Cross D.J., Galasko D., Schellenberg G.D., Raskind M.A., Peskind E.R., Minoshima S. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Arch. Neurol. 2009, 66:632-637.
140. Pitsikas N., Algeri S. Deterioration of spatial and nonspatial reference and working memory in aged rats: protective effect of life-long calorie restriction. Neurobiol. Aging 1992, 13:369-373.
141. Praticò D., Uryu K., Leight S., Trojanoswki J.Q., Lee V.M. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 2001, 21:4183-4187.
142. Price J.L., Morris J.C. Tangles and plaques in nondemented aging and " preclinical" Alzheimer's disease. Ann. Neurol. 1999, 45:358-368.
143. Price J.L., McKeel D.W., Buckles V.D., Roe C.M., Xiong C., Grundman M., Hansen L.A., Petersen R.C., Parisi J.E., Dickson D.W., et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol. Aging 2009, 30:1026-1036.
144. Qin W., Zhao W., Ho L., Wang J., Walsh K., Gandy S., Pasinetti G.M. Regulation of forkhead transcription factor FoxO3a contributes to calorie restriction-induced prevention of Alzheimer's disease-type amyloid neuropathology and spatial memory deterioration. Ann. N Y Acad. Sci. 2008, 1147:335-347.
145. Ramsden M., Kotilinek L., Forster C., Paulson J., McGowan E., SantaCruz K., Guimaraes A., Yue M., Lewis J., Carlson G., et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J. Neurosci 2005, 25:10637-10647.
146. Rapp P.R., Gallagher M. Preserved neuron number in the hippocampus of aged rats with spatial learning deficits. Proc. Natl. Acad. Sci. USA 1996, 93:9926-9930.
147. Reiman E.M., Caselli R.J., Yun L.S., Chen K., Bandy D., Minoshima S., Thibodeau S.N., Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N. Engl. J. Med. 1996, 334:752-758.
148. Reiman E.M., Caselli R.J., Chen K., Alexander G.E., Bandy D., Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2001, 98:3334-3339.
149. Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., Saunders A.M., Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl. Acad. Sci. USA 2004, 101:284-289.
150. Ridha B.H., Barnes J., Bartlett J.W., Godbolt A., Pepple T., Rossor M.N., Fox N.C. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol. 2006, 5:828-834.
151. Robakis N.K., Ramakrishna N., Wolfe G., Wisniewski H.M. Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides. Proc. Natl. Acad. Sci. USA 1987, 84:4190-4194.
152. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
153. Rosenmann H., Grigoriadis N., Eldar-Levy H., Avital A., Rozenstein L., Touloumi O., Behar L., Ben-Hur T., Avraham Y., Berry E., et al. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Exp. Neurol. 2008, 212:71-84.
154. Rossner S., Mehlhorn G., Schliebs R., Bigl V. Increased neuronal and glial expression of protein kinase C isoforms in neocortex of transgenic Tg2576 mice with amyloid pathology. Eur. J. Neurosci. 2001, 13:269-278.
155. Rossor M.N., Fox N.C., Freeborough P.A., Harvey R.J. Clinical features of sporadic and familial Alzheimer's disease. Neurodegeneration 1996, 5:393-397.
156. Rovelet-Lecrux A., Hannequin D., Raux G., Le Meur N., Laquerrière A., Vital A., Dumanchin C., Feuillette S., Brice A., Vercelletto M., et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 2006, 38:24-26.
157. Rozkalne A., Spires-Jones T.L., Stern E.A., Hyman B.T. A single dose of passive immunotherapy has extended benefits on synapses and neurites in an Alzheimer's disease mouse model. Brain Res. 2009, 1280:178-185.
158. Rusinek H., De Santi S., Frid D., Tsui W.H., Tarshish C.Y., Convit A., de Leon M.J. Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology 2003, 229:691-696.
159. Sanchez-Mejia R.O., Newman J.W., Toh S., Yu G.Q., Zhou Y., Halabisky B., Cissé M., Scearce-Levie K., Cheng I.H., Gan L., et al. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat. Neurosci. 2008, 11:1311-1318.
160. Santacruz K., Lewis J., Spires T., Paulson J., Kotilinek L., Ingelsson M., Guimaraes A., DeTure M., Ramsden M., McGowan E., et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309:476-481.
161. Schindowski K., Bretteville A., Leroy K., Bégard S., Brion J.P., Hamdane M., Buée L. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am. J. Pathol. 2006, 169:599-616.
162. Schneider J.A., Arvanitakis Z., Bang W., Bennett D.A. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007, 69:2197-2204.
163. Schneider J.A., Aggarwal N.T., Barnes L., Boyle P., Bennett D.A. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J. Alzheimers Dis. 2009, 18:691-701.
164. Schneider J.A., Arvanitakis Z., Leurgans S.E., Bennett D.A. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann. Neurol. 2009, 66:200-208.
165. Schwab C., Hosokawa M., McGeer P.L. Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp. Neurol. 2004, 188:52-64.
166. Senechal Y., Kelly P.H., Cryan J.F., Natt F., Dev K.K. Amyloid precursor protein knockdown by siRNA impairs spontaneous alternation in adult mice. J. Neurochem. 2007, 102:1928-1940.
167. Senechal Y., Kelly P.H., Dev K.K. Amyloid precursor protein knockout mice show age-dependent deficits in passive avoidance learning. Behav. Brain Res. 2008, 186:126-132.
168. Shankar S., Teyler T.J., Robbins N. Aging differentially alters forms of long-term potentiation in rat hippocampal area CA1. J. Neurophysiol. 1998, 79:334-341.
169. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
170. Shrestha B.R., Vitolo O.V., Joshi P., Lordkipanidze T., Shelanski M., Dunaevsky A. Amyloid beta peptide adversely affects spine number and motility in hippocampal neurons. Mol. Cell. Neurosci. 2006, 33:274-282.
171. Sleegers K., Brouwers N., Gijselinck I., Theuns J., Goossens D., Wauters J., Del-Favero J., Cruts M., van Duijn C.M., Van Broeckhoven C. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 2006, 129:2977-2983.
172. Small G.W., Ercoli L.M., Silverman D.H., Huang S.C., Komo S., Bookheimer S.Y., Lavretsky H., Miller K., Siddarth P., Rasgon N.L., et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2000, 97:6037-6042.
173. Smith M.A., Hirai K., Hsiao K., Pappolla M.A., Harris P.L., Siedlak S.L., Tabaton M., Perry G. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem. 1998, 70:2212-2215.
174. Snowdon D.A., Greiner L.H., Mortimer J.A., Riley K.P., Greiner P.A., Markesbery W.R. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997, 277:813-817.
175. Snyder E.M., Nong Y., Almeida C.G., Paul S., Moran T., Choi E.Y., Nairn A.C., Salter M.W., Lombroso P.J., Gouras G.K., Greengard P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci. 2005, 8:1051-1058.
176. Spires T.L., Meyer-Luehmann M., Stern E.A., McLean P.J., Skoch J., Nguyen P.T., Bacskai B.J., Hyman B.T. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J. Neurosci. 2005, 25:7278-7287.
177. Spires T.L., Orne J.D., SantaCruz K., Pitstick R., Carlson G.A., Ashe K.H., Hyman B.T. Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am. J. Pathol. 2006, 168:1598-1607.
178. Spires-Jones T.L., Meyer-Luehmann M., Osetek J.D., Jones P.B., Stern E.A., Bacskai B.J., Hyman B.T. Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. Am. J. Pathol. 2007, 171:1304-1311.
179. Stern E.A., Bacskai B.J., Hickey G.A., Attenello F.J., Lombardo J.A., Hyman B.T. Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. J. Neurosci. 2004, 24:4535-4540.
180. Stoothoff W., Jones P.B., Spires-Jones T.L., Joyner D., Chhabra E., Bercury K., Fan Z., Xie H., Bacskai B., Edd J., et al. Differential effect of three-repeat and four-repeat tau on mitochondrial axonal transport. J. Neurochem. 2009, 111:417-427.
181. Storandt M., Mintun M.A., Head D., Morris J.C. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch. Neurol. 2009, 66:1476-1481.
182. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Bürki K., Frey P., Paganetti P.A., et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA 1997, 94:13287-13292.
183. Stutzmann G.E. The pathogenesis of Alzheimers disease is it a lifelong " calciumopathy" ?. Neuroscientist 2007, 13:546-559.
184. Swearer J.M., O'Donnell B.F., Drachman D.A., Woodward B.M. Neuropsychological features of familial Alzheimer's disease. Ann. Neurol. 1992, 32:687-694.
185. Takeda T. Senescence-accelerated mouse (SAM): a biogerontological resource in aging research. Neurobiol. Aging 1999, 20:105-110.
186. Takeda T., Hosokawa M., Takeshita S., Irino M., Higuchi K., Matsushita T., Tomita Y., Yasuhira K., Hamamoto H., Shimizu K., et al. A new murine model of accelerated senescence. Mech. Ageing Dev. 1981, 17:183-194.
187. Tampellini D., Rahman N., Gallo E.F., Huang Z., Dumont M., Capetillo-Zarate E., Ma T., Zheng R., Lu B., Nanus D.M., et al. Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations. J. Neurosci. 2009, 29:9704-9713.
188. Tanzi R.E., Gusella J.F., Watkins P.C., Bruns G.A.P., St George-Hyslop P., Van Keuren M.L., Patterson D., Pagan S., Kurnit D.M., Neve R.L. Amyloid β protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987, 235:880-884.
189. Tomiyama T., Nagata T., Shimada H., Teraoka R., Fukushima A., Kanemitsu H., Takuma H., Kuwano R., Imagawa M., Ataka S., et al. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann. Neurol. 2008, 63:377-387.
190. Tonkikh A., Janus C., El-Beheiry H., Pennefather P.S., Samoilova M., McDonald P., Ouanounou A., Carlen P.L. Calcium chelation improves spatial learning and synaptic plasticity in aged rats. Exp. Neurol. 2006, 197:291-300.
191. Urbanc B., Cruz L., Le R., Sanders J., Ashe K.H., Duff K., Stanley H.E., Irizarry M.C., Hyman B.T. Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2002, 99:13990-13995.
192. Uryu K., Nakashima-Yasuda H., Forman M.S., Kwong L.K., Clark C.M., Grossman M., Miller B.L., Kretzschmar H.A., Lee V.M., Trojanowski J.Q., Neumann M. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J. Neuropathol. Exp. Neurol. 2008, 67:555-564.
193. Vitek M.P., Snell J., Dawson H., Colton C.A. Modulation of nitric oxide production in human macrophages by apolipoprotein-E and amyloid-beta peptide. Biochem. Biophys. Res. Commun. 1997, 240:391-394.
194. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
195. Webster S.D., Tenner A.J., Poulos T.L., Cribbs D.H. The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation. Neurobiol. Aging 1999, 20:297-304.
196. Weingarten M.D., Lockwood A.H., Hwo S.Y., Kirschner M.W. A protein factor essential for microtubule assembly. Proc. Natl. Acad. Sci. USA 1975, 72:1858-1862.
197. Westerman M.A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L.H., Carlson G.A., Younkin S.G., Ashe K.H. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 2002, 22:1858-1867.
198. Westmark C.J., Westmark P.R., Beard A.M., Hildebrandt S.M., Malter J.S. Seizure susceptibility and mortality in mice that over-express amyloid precursor protein. Int J Clin Exp Pathol 2008, 1:157-168.
199. Wilson I.A., Ikonen S., Gallagher M., Eichenbaum H., Tanila H. Age-associated alterations of hippocampal place cells are subregion specific. J. Neurosci. 2005, 25:6877-6886.
200. Wirths O., Breyhan H., Cynis H., Schilling S., Demuth H.U., Bayer T.A. Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol. 2009, 118:487-496.
201. Wong T.P., Debeir T., Duff K., Cuello A.C. Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J. Neurosci. 1999, 19:2706-2716.
202. Yoshiike Y., Kimura T., Yamashita S., Furudate H., Mizoroki T., Murayama M., Takashima A. GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. PLoS ONE 2008, 3:e3029.
203. Yoshiyama Y., Higuchi M., Zhang B., Huang S.M., Iwata N., Saido T.C., Maeda J., Suhara T., Trojanowski J.Q., Lee V.M. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53:337-351.
204. Zhao L., Ma Q.L., Calon F., Harris-White M.E., Yang F., Lim G.P., Morihara T., Ubeda O.J., Ambegaokar S., Hansen J.E., et al. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat. Neurosci. 2006, 9:234-242.